These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3532942)

  • 1. Imipenem-cilastatin as initial therapy for febrile cancer patients.
    Bodey GP; Alvarez ME; Jones PG; Rolston KV; Steelhammer L; Fainstein V
    Antimicrob Agents Chemother; 1986 Aug; 30(2):211-4. PubMed ID: 3532942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem/cilastatin therapy of infections in cancer patients.
    Bodey GP; Elting L; Jones P; Alvarez ME; Rolston K; Fainstein V
    Cancer; 1987 Jul; 60(2):255-62. PubMed ID: 3297282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem/cilastatin as secondary therapy for infections in cancer patients.
    Bodey GP; Rolston K; Jones P; Alvarez ME; Fainstein V; Steelhammer L
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():161-6. PubMed ID: 3469189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cefoperazone and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients.
    Mortimer J; Miller S; Black D; Kwok K; Kirby WM
    Am J Med; 1988 Jul; 85(1A):17-20. PubMed ID: 3400679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of imipenem/cilastatin in patients with severe bacterial infections.
    Reutter FW
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():141-4. PubMed ID: 3469186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe gram-negative infections in neutropenic children cured by imipenem/cilastatin in combination with an aminoglycoside.
    Baruchel A; Hartmann O; Andremont A; Tancrède C
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():167-73. PubMed ID: 3469190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerability of imipenem/cilastatin in infections at various sites].
    Grassi C; Baglioni A; Bonsignore G; Catena E; De Rose V; Grignani F; Lotti T; Orlandi O; Panichi G; Pavone Macaluso M
    G Ital Chemioter; 1986; 33(2-3):143-8. PubMed ID: 3479372
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dosage of imipenem/cilastatin].
    Shah PM
    Infection; 1986; 14 Suppl 2():S143-7. PubMed ID: 3759249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem/cilastatin: the first carbapenem antibiotic.
    Lyon JA
    Drug Intell Clin Pharm; 1985 Dec; 19(12):895-9. PubMed ID: 3910385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of moderate or severe infections using imipenem/cilastatin. 41 cases based on a multicenter protocol].
    Stahl JP; Chavanet P; Robert D; Croize J; Mercatello A; Bru JP; Aguilaniu F; Portier H; Micoud M
    Pathol Biol (Paris); 1986 May; 34(5):465-9. PubMed ID: 3534723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
    Liang R; Yung R; Chiu E; Chau PY; Chan TK; Lam WK; Todd D
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1336-41. PubMed ID: 2201252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam.
    Calandra GB; Hesney M; Grad C
    Eur J Clin Microbiol; 1984 Oct; 3(5):478-87. PubMed ID: 6389126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imipenem/cilastatin in the empirical treatment of septicemia.
    Del Valle J; Noriega AR; Sanz F; Revilla AP; Otero JR
    Scand J Infect Dis Suppl; 1987; 52():20-5. PubMed ID: 3331040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin.
    Marier RL; McCloskey RV; Dickenson G; Sanders CV; Aldridge KE; Hoffman T; Gutterman D; Janney A
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():133-9. PubMed ID: 6365873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of bronchopulmonary infections in patients during artificial respiration with imipenem/cilastatin].
    Unertl K; Lenhart FP; Ruckdeschel G
    Immun Infekt; 1986 Nov; 14(6):229-31. PubMed ID: 3100428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Calculated initial chemotherapy in mechanically-ventilated postoperative patients with peritonitis, sepsis and pneumonia].
    Hünefeld G; Weissbrodt H; Aebert H; Bunzendahl H
    Infection; 1986; 14 Suppl 2():S164-70. PubMed ID: 3759251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of nosocomial pneumonia following imipenem/cilastatin therapy.
    Rapp RP; Young B; Bertch K; Tibbs P; Foster TS
    Drug Intell Clin Pharm; 1987 Mar; 21(3):272-6. PubMed ID: 3471433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.